1616923-16-0

Basic information

• Product Name: 5-benzyloxy-2-(2-bromobenzyl)-6-oxo-3,6-dihydropyrimidine-4-carboxylic acid tert-butyl ester
• Synonyms: 5-benzyloxy-2-(2-bromobenzyl)-6-oxo-3,6-dihydropyrimidine-4-carboxylic acid tert-butyl ester
• CAS NO: 1616923-16-0
• Molecular Weight: 471.351
• Mol File: 1616923-16-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 5-benzyloxy-2-(2-bromobenzyl)-6-oxo-3,6-dihydropyrimidine-4-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 5-benzyloxy-2-(2-bromobenzyl)-6-oxo-3,6-dihydropyrimidine-4-carboxylic acid tert-butyl ester(1616923-16-0)
• EPA Substance Registry System: 5-benzyloxy-2-(2-bromobenzyl)-6-oxo-3,6-dihydropyrimidine-4-carboxylic acid tert-butyl ester(1616923-16-0)

Safety Data

• Hazardous Substances Data: 1616923-16-0(Hazardous Substances Data)

Upstream product

• 127813-37-0 2-(2-bromophenyl)acetimidamide hydrochloride 
• 31600-43-8 methyl 2-(benzyloxy)acetate 
• 30379-55-6 benzyloxyacetic acid 

Downstream Products

• 1616923-17-1 5-benzyloxy-2-(2-bromobenzyl)-6-oxo-3,6-dihydropyrimidine-4-carboxylic acid 
• 1616923-18-2 5-benzyloxy-2-(2-bromobenzyl)-6-oxo-3,6-dihydropyrimidine-4-carboxylic acid [2-(tert-butyldimethylsilanyloxy)ethyl]isopropylamide 
• 1616923-19-3 5-benzyloxy-2-(2-bromobenzyl)-6-oxo-3,6-dihydropyrimidine-4-carboxylic acid (2-hydroxyethyl)isopropylamide 
• 1616923-20-6 9-benzyloxy-6-(2-bromobenzyl)-2-isopropyl-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,8-dione 
• 1616921-78-8 6-(3',4'-dichlorobiphenyl-2-ylmethyl)-9-hydroxy-2-isopropyl-3,4-dihydro-2H-pyrazino[1,2-c]pyrimidine-1,8-dione 
• 1616923-86-4 9-benzyloxy-6-[[2-(3,4-difluorophenyl)phenyl]methyl]-2-isopropyl-3,4-dihydropyrazino[1,2-c]pyrimidine-1,8-dione 
• 1616921-95-9 6-[[2-(3,4-difluorophenyl)phenyl]methyl]-9-hydroxy-2-isopropyl-3,4-dihydropyrazino[1,2-c]pyrimidine-1,8-dione 

Relevant articles and documents

PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE

The present invention relates to a compound having the general formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.